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The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive
therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug
discovery projects for inflammation, asthma, pain, cancer, Parkinson’s, and Alzheimer’s
diseases, which includes searches for dual acting H3R/H4R ligands. In the present work,
nine 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazine (LINS01 series) molecules
were synthesized and evaluated as H3R and H4R ligands. Our data show that the
N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pK i 6.40),
while the chlorinated compound LINS01007 has moderate affinity for H4R (pK i 6.06). In
addition, BRET assays to assess the functional activity of Gi1 coupling indicate that
all compounds have no intrinsic activity and act as antagonists of these receptors.
Drug-likeness assessment indicated these molecules are promising leads for further
improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse
model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than
the previously tested compound LINS01005. This is the first report with functional data
of these compounds in HRs, and our results also show the potential of their applications
as anti-inflammatory.
Keywords: H3R antagonists, H4R antagonists, histamine receptors, dihydrobenzofuran, SAR, anti-inflammatory
activity, asthma
INTRODUCTION
Histamine is one of the most important chemical transmitters involved in several biological
processes. It has been widely studied since its discovery1−3 due to its role in inflammatory and
allergic reactions, but it is also involved in the regulation of gastric acid secretion, sleep, mood,
and food intake (Passani and Blandina, 2011). These processes are triggered by the interaction of
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histamine with its receptors (HRs), named H1R, H2R, H3R,
and H4R. HRs are members of the G protein-coupled
receptor (GPCR) class A family, which are also known as 7
transmembrane (7TM) receptors (Seifert et al., 2011; Corrêa and
Fernandes, 2015).
The H3R is mainly found in CNS, and is involved in the
inhibition of histamine release, as well as in the inhibition of
other neurotransmitters, such as norepinephrine, acetylcholine,
and serotonin (Leurs et al., 2005). Therefore, H3R modulates
neurotransmitters release by acting as a presynaptic receptor
(auto- and hetero-receptor). It has been previously reported
that signal transduction by H3R occurs mainly by activation
of Gi/o proteins, leading to decrease of intracellular cAMP
concentration and decrease of Ca2+ influx in neurons (Tiligada
et al., 2009). As a result of its actions, H3R could be involved
in several neurological disorders, including cognitive, convulsive,
and sleep–wake disorders, as well as in obesity (Łaz˙ewska et al.,
2014). Therefore, H3R ligands could be promising drugs to
treat these conditions. H3R ligands have been widely explored.
Recently, the novel H3R antagonist pitolisant has been approved
for treatment of narcolepsy, highlighting the importance of this
receptor as a new target for treatment of certain CNS disorders
(Sayed, 2016). Ciproxifan and ABT-239 (Figure 1) are other
examples of such well-studied compounds.
In the early 2000s, several research groups described a
new isoform of HR, expressed in immune cells (eosinophils,
basophils, mast cells, NK cells, DCs, monocytes, and T cells),
which is involved in the modulation of chemotaxis as well
as other functions (Oda et al., 2000; Liu et al., 2001). This
receptor was named H4R, is also coupled to Gi/o proteins
(Corrêa and Fernandes, 2015), and bears a considerable sequence
identity to H3R (∼31% total, 54% in TM domains) (Oda
et al., 2000; Liu et al., 2001). Considering the physico-chemical
properties of the different amino acids, this similarity in TM
domains can reach 68% (de Esch et al., 2005). Since these
cells are involved in immune and inflammatory processes, H4R
is considered a promising target to future anti-inflammatory
and modulatory immunological drugs. H4R ligands have been
designed and evaluated as drug candidates (Figure 1), with
the indolecarboxamides (JNJ-7777120) and 2-aminopyrimidines
(A-943931) being the most explored chemotypes in this
regard. Some molecules lacking the carbonyl group from the
indolecarboxamides were also identified as H4R ligands in virtual
screening experiments (Christopher et al., 2012).
Due to the high sequence identity between H3R and H4R,
it is likely that several compounds that bind to one of them
can present considerable affinity for the other. Hence, some
pharmacophore templates to H3R ligands can also be applied to
H4R ligands (Kottke et al., 2011). In fact, the search for selective
ligands that are able to discriminate one of those receptors
is frequently reported in the literature, and most medicinal
chemists working with HR-ligand research have such selectivity
parameter as one of the most important goals. However, dual-
acting H3R/H4R ligands may also present therapeutic potential
in determined pathological conditions, such as neuropathic
pain (Smith et al., 2007), cancer (Medina et al., 2008), and
have also been reported in Parkinson’s disease (Shan et al.,
2015a,b). Such potential applications were already reported for
imidazole-containing H3R/H4R ligands, such as imetit, immepip,
clobenpropit, and thioperamide.
To the best of our knowledge, the functional activity of
dihydrobenzofuran-containing molecules have not yet evaluated
in the H3R and H4R until the present report. The affinities
to these receptors were evaluated as well. Considering the
chemical similarities observed for several H3R and H4R ligands,
we have designed a set of 1-[(2,3-dihydro-1-benzofuran-2-
yl)methyl]piperazines (LINS01 series – 1a–i), evaluated their
affinity and selectivity for those receptors, and characterized
their functional activities. Drug-likeness was also assessed to
define some structure-activity relationship (SAR) roles in this
set of compounds, and an evaluation of the anti-inflammatory
potential of a selected molecule was carried out in a mouse
asthma model.
MATERIALS AND METHODS
Reagents and starting materials were obtained from commercial
suppliers (Sigma–Aldrich Co., Saint Louis, MO, United States;
LabSynt Co., Diadema, Brazil) and used without further
purification. 1H and 13C NMR spectra were recorded in a Bruker
Ultrashield 300 spectrometer, operating at 300 and 75 MHz,
respectively, using CDCl3 as solvent with TMS as internal
standard. Chemical shifts are reported in parts per million (ppm,
δ units). Coupling constants (J) are reported in units of hertz
(Hz), if applicable. The high resolution mass spectra (HRMS)
were obtained through direct injection after electron-spray
ionization in positive mode (ESI+) in a MicroTOF from Bruker
Daltonics mass spectrometer. Gas chromatography coupled to
mass spectrometer (GC-MS) analysis were done in a Shimadzu
GC-2010 coupled to mass spectrometer GCMS-QP2010 plus,
using helium as carrier gas in a silica capillary column. The low
resolution mass spectra (LRMS) were obtained through electron
impact ionization (70 eV). The ion-radical and its fragments
are reported in mass/charge ratio (m/z). The purity (>95%)
for the final compounds 1a–i were determined and confirmed
(H2O/MeOH 50%) by HPLC in a C-18 column coupled to UV
detector (254 nm). Only compounds with >95% purity were
considered to the biological assays. The yields for each step are
summarized in Table 1. Spectral data and characterization for the
intermediates can be found in Supplementary Information.
Synthetic Procedure for Intermediates
2–5
The intermediate compounds (Figure 2 and Supplementary
Figure S1) were synthesized according to previously reported
procedures from our group (Corrêa et al., 2016, 2017). The
experimental details can be found in the Supplementary
Information.
General Procedure for the Synthesis of
Final Products (1a–i)
In a round-bottom flask, were added 2 mmol of corresponding
2-iodomethyl-2,3-dihydrobenzofuran (4a–h), 2.8 mmol (0.379 g)
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FIGURE 1 | Characteristics considered in the design of LINS compounds 1a–i; green – aromatic core; orange – polar group; blue – additional lipophilic group.
of K2CO3, and 8 mmol of corresponding 1-substituted piperazine
in 15 mL of tetrahydrofuran. The mixture was reacted at 70◦C
for 18–24 h. The reactional mixture was filtered, the solvent
removed under vacuum, and the residue was taken up in 1
M HCl solution (pH < 2), and washed with 2 × 10 mL of
hexane. The aqueous phase was alkalinized (pH > 12) with 1
M NaOH solution, and extracted 3 × 10 mL of ethyl acetate.
The organic layer was dried with anhydrous Na2SO4 and filtered.
The solution was filtered over silica gel to remove any piperazine
remaining, and the solvent removed under vacuum. If necessary,
column chromatography in silica gel was used to purify the
compounds, using dichloromethane:methanol (8:1) as eluent
(Figure 2).
1-[(2,3-Dihydro-1-benzofuran-2-yl)methyl]piperazine (1a).
Yellowish solid. mp 118–121◦C. 1H NMR (CDCl3, 300 MHz): δ
2.45–2.70 (m, 8H), 2.79 (dd, 1H, J = 13.2, 7.7 Hz), 2.88–3.00 (m,
TABLE 1 | Yields obtained for the synthesis of compounds 1a–i.
Compounds Yield (%)
Step a Step b Step c Step d
1a – – 90 83
1b 85
1c 66
1d 50
1e 86 80 89 59
1f 87 79 88 50
1g 70 85 92 65
1h 84 73 89 69
1i 86 80 89 45
2H), 3.27 (dd, 1H, J = 15.7, 9.3 Hz), 4.89–5.04 (m, 1H), 6.77–6.88
(m, 2H), 7.08–7.20 (m, 2H). 13C NMR (CDCl3, 75 MHz): δ
34.3, 51.4, 53.9, 63.4, 80.8, 109.6, 120.3, 124.9, 126.5, 127.9,
159.6. LRMS (EI) m/z (rel %): 218 (15) [M+], 99 (100), 70 (26).
HRMS (ESI+) for C13H18N2O [M+H]+: calcd 219.1493; found
219.1523.
1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]-4-methylpipera-
zine (1b). Yellowish solid. mp 45–49◦C. 1H NMR (CDCl3,
300 MHz): δ 2.30 (s, 3H), 2,49 (br.s, 4H), 2.57 (dd, 1H, J = 13.4,
4.4 Hz), 2.63 (br.s, 4H), 2.79 (dd, 1H, J = 13.4, 7.8 Hz), 2.94 (dd,
1H, J = 15.6, 7.8 Hz), 3.26 (dd, 1H, J = 15.6, 9.2 Hz), 4.95 (dq,
1H, J = 9.0, 3.9 Hz), 6.75–6.85 (m, 2H), 7.06–7.20 (m, 2H). 13C
NMR (CDCl3, 75 MHz): δ 34.2, 46.0, 53.8, 55.0, 63.2, 80.8, 109.6,
120.3, 124.9, 126.4, 128.0, 159.5. LRMS (EI) m/z (rel %): 232
(18) [M+], 113 (95), 70 (100). HRMS (ESI+) for C14H20N2O
[M+H]+: calcd 233.1649; found 233.1683.
1-allyl-4-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazine
(1c). Yellowish oil. 1H NMR (CDCl3, 300 MHz): δ 2.38–2.72
(m, 8H), 2.57 (dd, 1H, J = 13.3, 4.1 Hz), 2.79 (dd, 1H, J = 13.3,
8.1 Hz), 2.94 (dd, 1H, J = 15.6, 8.1 Hz), 3.01 (dq, 2H, J = 6.6,
1.4 Hz), 3.26 (dd, 1H, J = 15.5, 9.1 Hz), 4.95 (dq, 1H, J = 9.1,
4.1 Hz), 5.09–5.26 (m, 2H), 5.78–5.96 (m, 1H), 6.75–6.88 (m,
2H), 7.05–7.21 (m, 2H). 13C NMR (CDCl3, 75 MHz): δ 34.2,
53.0, 53.8, 61.8, 63.3, 80.8, 109.7, 118.0, 120.3, 124.9, 126.5, 128.0,
135.1, 159.5. LRMS (EI) m/z (rel %): 258 (23) [M+], 139 (100), 70
(27). HRMS (ESI+) for C16H22N2O [M+H]+: calcd 259.1806;
found 259.1840.
1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]-4-phenyl-
piperazine (1d). Yellowish solid. mp 47–51◦C. 1H NMR (CDCl3,
300 MHz): δ 2.64 (dd, 1H, J = 13.4, 4.2 Hz) 2.69–2.83 (m,
4H), 2.85 (dd, 1H, J = 13.2, 7.7 Hz), 3.05 (dd, 1H, J = 15.5,
7.7 Hz), 3.21–3.35 (m, 5H), 4.95–5.06 (m, 1H), 6.76–6.90 (m,
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FIGURE 2 | Reaction scheme for the synthesis of LINS01 compounds.
3H), 6.91–6.97 (m, 2H), 7.07–7.20 (m, 2H), 7.23–7.31 (m, 2H).
13C NMR (CDCl3, 75 MHz): δ 34.2, 49.1, 53.9, 63.2, 80.8, 109.7,
116.1, 119.7, 120.4, 124.9, 126.4, 128.1, 129.1, 151.4, 159.5. LRMS
(EI) m/z (rel %): 294 (25) [M+], 175 (100), 70 (69). HRMS (ESI+)
for C19H22N2O [M+H]+: calcd 295.1806; found 295.1846.
1-[(5-chloro-2,3-dihydro-1-benzofuran-2-yl)methyl]-4-
methylpiperazine (1e). Yellow oil. 1H NMR (CDCl3, 300 MHz):
δ 2.33 (s, 3H), 2.55 (br.s, 4H), 2.57 (dd, 1H, J = 13.4, 4.2 Hz),
2.65 (br.s, 4H), 2.78 (dd, 1H, J = 13.4, 7.7 Hz), 2.94 (dd, 1H,
J = 15.9, 8.0 Hz), 3.24 (dd, 1H, J = 15.9, 9.1 Hz), 4.91–5.03 (m,
1H), 6.68 (d, 1H, J = 8.4 Hz), 7.04 (dd, 1H, J = 8.4, 2.3 Hz),
7.09–7.11 (m, 1H).13C NMR (CDCl3, 75 MHz): δ 34.0, 45.9, 53.5,
54.9, 62.8, 81.5, 110.5, 125.0, 127.9, 128.4, 128.5, 158.2. LRMS
(EI) m/z (rel %): 266 (8) [M+], 113 (97), 70 (100). HRMS (ESI+)
for C14H19ClN2O [M+H]+: calcd 267.1259; found 267.1231.
1-methyl-4-[(5-methyl-2,3-dihydro-1-benzofuran-2-yl)
methyl]piperazine (1f). Yellow oil. 1H NMR (CDCl3, 300 MHz):
δ 2.26 (s, 3H), 2.29 (s, 3H), 2.49 (br.s, 4H), 2.55 (dd, 1H, J = 13.4,
4.2 Hz), 2.62 (br.s, 4H), 2.78 (dd, 1H, J = 13.4, 7.7 Hz), 2.90 (dd,
1H, J = 15.5, 8.0 Hz), 3.22 (dd, 1H, J = 15.5, 9.0 Hz), 4.86–4.99
(m, 1H), 6.67 (d, 1H, J = 8.1 Hz), 6.89 (d, 1H, J = 7.9 Hz), 6.96
(s, 1H). 13C NMR (CDCl3, 75 MHz): δ 20.8, 34.3, 46.1, 53.8, 55.0,
63.2, 80.8, 109.1, 125.5, 126.5, 128.3, 129.6, 157.4. LRMS (EI) m/z
(rel %): 245 (25) [M+], 113 (100), 70 (85). HRMS (ESI+) for
C15H22N2O [M+H]+: calcd 247.1806; found 247.1817.
1-methyl-4-[(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)
methyl]piperazine (1g). Yellow oil. 1H NMR (CDCl3, 300 MHz):
δ 2.30 (s, 3H), 2.30–2.90 (br.s, 8H), 2.57 (dd, 1H, J = 13.2,
3.8 Hz), 2.78 (dd, 1H, J = 13.2, 8.1 Hz), 2.94 (dd, 1H, J = 15.7,
8.1 Hz), 3.24 (dd, 1H, J = 15.7, 9.0 Hz), 3.75 (s, 3H), 4.95 (dq,
1H, J = 8.4, 3.8 Hz), 6.64 (dd, 1H, J = 8.6, 2.3 Hz), 6.71 (d,
1H, J = 8.6 Hz), 6.75 (d, 1H, J = 2.3 Hz). 13C NMR (CDCl3,
75 MHz): δ 34.7, 46.1, 53.8, 54.9, 56.0, 63.3, 80.8, 109.5, 111.2,
112.6, 127.5, 153.6, 153.9. LRMS (EI) m/z (rel %): 294 (25) [M+],
175 (100), 70 (69). LRMS (EI) m/z (rel %): 262 (28) [M+], 113
(100), 70 (85). HRMS (ESI+) for C15H22N2O2 [M+H]+: calcd
263.1754; found 263.1755.
1-methyl-4-[(5-tert-butyl-2,3-dihydro-1-benzofuran-2-yl)
methyl]piperazine (1h). Yellowish solid. mp 90–93◦C. 1H NMR
(CDCl3, 300 MHz): δ 1.29 (s, 9H), 2.30 (s, 3H), 2.50 (br.s, 4H),
2.58 (dd, 1H, J = 13.4, 4.2 Hz), 2.64 (br.s, 4H), 2.81 (dd, 1H,
J = 13.4, 7.8 Hz), 2.95 (dd, 1H, J = 15.5, 8.1 Hz), 3.27 (dd, 1H,
J = 15.5, 9.1 Hz), 4.96 (dq, 1H, J = 8.3, 4.1 Hz), 6.72 (d, 1H,
J = 8.1 Hz), 7.14 (d, 1H, J = 8.5 Hz), 7.19 (s, 1H). 13C NMR
(CDCl3, 75 MHz): δ 31.8, 34.3, 34.5, 46.0, 53.8, 55.0, 63.4, 80.9,
108.8, 121.9, 124.7, 126.0, 143.4, 157.3. LRMS (EI) m/z (rel %):
288 (14) [M+], 113 (100), 70 (65). HRMS (ESI+) for C18H28N2O
[M+H]+: calcd 289.2274; found 289.2263.
1-[(5-chloro-2,3-dihydro-1-benzofuran-2-yl)methyl]-4-
phenylpiperazine (1i). Yellow oil. 1H NMR (CDCl3, 300 MHz): δ
2.63 (dd, 1H, J = 13.4, 4.2 Hz), 2.75 (q, 4H, J = 4.4 Hz), 2.83 (dd,
1H, J = 13.4, 7.8 Hz), 2.98 (dd, 1H, J = 15.7, 7.8 Hz), 3.20–3.32
(m, 5H), 5.02 (m, 1H), 6.70 (d, 1H, J = 8.4 Hz), 6.71 (d, 1H,
J = 8.4 Hz), 6.86 (dt, 1H, J = 7.1, 0.9 Hz), 6.91–6.95 (m, 2H),
7.03–7.08 (m, 1H), 7.10–7.14 (m, 1H), 7.23–7.30 (m, 2H). 13C
NMR (CDCl3, 75 MHz): δ 34.3, 48.0, 53.3, 61.9, 79.7, 110.6,
116.7, 120.9, 125.1, 125.8, 127.5, 128.2, 129.3, 150.3, 157.6. LRMS
(EI) m/z (rel %): 328 (8) [M+], 175 (100), 70 (72). HRMS (ESI+)
for C19H21ClN2O [M+H]+: calcd 329.1415; found 329.1413.
Cell Culture and Transfection
HEK293T cells were cultured in DMEM supplemented with 10%
fetal bovine serum, 100 U/ml penicillin/streptomycin, at 37◦C
in 5% CO2; 48 h before the binding assays, cells seeded in 10-
cm dishes were transiently transfected with H3R or H4R using
polyethylenimine (PEI; 25 kDa linear; Polysciences, Warrington,
PA, United States) at a ratio of 3:1 PEI/DNA. For BRET assays,
cells were transfected in suspension, using the same PEI/DNA
ratio as for attached cells, and directly seeded in 96-well white
plates (OptiPlate; PerkinElmer) at a density of 4 × 104 cells/well
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and grown for 48 h at 37◦C in 5% CO2. When needed, total
DNA amount was adjusted with salmon sperm DNA (Invitrogen,
Carlsbad, CA, United States).
Binding Assays
Competition binding assays were performed in HEK293T cells
transiently expressing the H3R or H4R (Santos et al., 2015)
in order to assess the affinities of synthesized compounds
for each receptor. HEK293T cells transiently expressing H3R
or H4R were transferred to 24-well culture plates 24 h after
the transfection. One day after plating, the cells were washed
once with cold wash buffer (Tris–HCl buffer 25 mM, pH 7.4
containing NaCl 140 mM, MgCl2 5 mM, and 0.1% bovine serum
albumin). Cells were incubated with 1.15 nM [3H]-histamine
and increasing concentrations of non-radioactive histamine and
compounds as a competitor in cold binding buffer [Tris–HCl
25 mM, pH 7.4, including MgCl2 5 mM, 0.1% bovine serum
albumin, and 100 µg/mL bacitracin (Sigma–Aldrich, St. Louis,
MO, United States)]. Cells were maintained at 4◦C for at least
16 h, washed twice and then lysed with lysis buffer (48% urea, 2%
NONIDET P-40, acetic acid 3M). Cell lysates were transferred to
scintillation vials and 3 mL of scintillation liquid (ScintiSafeTM
Econo 1, Fisher Scientific, Santa Clara, CA, United States)
were added. Bound radioactivity was quantified on a Tri-Carb
20100TR liquid scintillation counter (PerkinElmer, Waltham,
MA, United States). The median inhibitory concentration
(IC50) of the tested compounds for displacement [3H]-
histamine was obtained from the concentration–response curves,
and then using the Cheng–Prusoff equation, the apparent
affinities [K i = IC50/(1 + [ligand]/Kd)] were calculated
(Cheng and Prusoff, 1973; Reis et al., 2007). Commercially
available compounds JNJ-7777120 and clobenpropit were used as
reference ligands of H4R and H3R, respectively.
Analysis of G Protein Activation by BRET
Assays
G protein activation was evaluated in HEK293T cells transiently
expressing H3R or H4R and a BRET-based biosensor composed
of Gαi fused to RLucII (in this case, Gi1-RLucII) and GFP10-
Gγ2, in the presence of the untagged Gβ1 subunit (Galés
et al., 2005). Cells were transfected in suspension, seeded in
96-well white plates (OptiPlate; PerkinElmer) and grown for
48 h. BRET values were monitored using VictorTM X Light
Luminescence microplate reader (PerkinElmer) equipped with
BRET400-GFP2/10 filter set (acceptor, 515 ± 20 nm; and donor,
400 ± 70 nm filters), 5 min after the addition of 2.5 µM of
coelenterazine 400-a (Biotium, Hayward, CA, United States) and
the analyzed ligands. In the antagonism assays, the different
ligands were incubated 30 min prior to stimulation with
histamine and addition of coelenterazine, according to the
procedure described earlier.
Calculated Physicochemical Properties
The molecular properties clogP (calculated lipophilicity), logS
(water solubility), molecular weight (MW), topological polar
surface area (TPSA) as well as the hydrogen-bond donor (HBD)
and acceptor (HBA), and the rotatable bonds (RotB) counts were
calculated using the MolSoft online software for drug-likeness
and molecular property prediction (La Jolla, CA, United States).
The drug-likeness score was also calculated by the software as a
prediction of the overall drug-likeness of the molecule based on
a MolSofts’s chemical fingerprint. Positive values mean similarity
to market drugs.
Ligand Metric Analyses
The metric analysis of a test molecule in a given target can be done
using values of ligand efficiency (LE), lipophilic ligand efficiency
(LLE), ligand efficiency dependent lipophilicity (LELP), and
group efficiency (GE) (Verdonk and Rees, 2008; Hopkins et al.,
2014). These metric values are widely employed in drug discovery
to indicate whether a potency value derives from a specific target
interaction or simply due to many unspecific contacts. These
values were calculated using the following equations (1)–(4).
LE = 1.37.pKi/HA (1)
LLE = pKi − ClogP (2)
LELP = ClogP/LE (3)
GE = (1.37.1pKi)/1HA (4)
Where HA is the number of heavy (non-hydrogen) atoms in the
molecule.
Animals
Male C57Bl/6 mice weighing 20–25 g, 6–8 weeks old, from
our own animal facilities were housed in a room with a 12 h
light–dark cycle with water and food ad libitum. Animal care
and research protocols were in accordance with the principles
and guidelines adopted by the Brazilian College of Animal
Experimentation (COBEA) and this project was approved by the
Ethical Committee for Animal Research of the Federal University
of São Paulo (CEUA 1666/99).
Induction of Allergic Asthma and
Treatments
Mice (n = 5 per group) were sensitized on days 0 and 7 by
an intraperitoneal injection of a mixture containing 50 mg of
ovalbumin (OVA; Grade V, Sigma–Aldrich, United States) and
1 mg of Al(OH)3 in PBS (a total volume of 0.2 ml). Mice were
challenged by exposure to an aerosol of OVA generated by an
ultrasonic nebulizer (ICEL US-800, SP, Brazil) delivering particles
of 0.5–10 mm diameter at approximately 0.75 cc/min for 20 min
at days 14 and 21. The concentration of OVA in the nebulizer
was 2.5% w/v in PBS. The control group consisted of animals
immunized as previously described and challenged two times
with PBS solution. Compounds 1d and 1e were administered
intraperitoneally in two different dosages (5 and 3 mg/kg) to the
test groups 30 min before the antigen challenge. Sensitized and
control groups were used to assess the anti-inflammatory activity
(Corrêa et al., 2017).
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Bronchoalveolar Lavage
Mice were euthanized with intraperitoneal ketamine and xylazine
(100 and 10 mg/kg, respectively; Agibrands do Brazil, São Paulo,
São Paulo, Brazil), 24 h after exposure to the last aerosol
challenge. A tracheal cannula was inserted via a mid cervical
incision, and the airways were washed twice with 1 ml of
phosphate-buffered saline (PBS, pH 7.4 at 4◦C).
Total and Differential Cell Counts in the
Bronchoalveolar Lavage Fluid
The bronchoalveolar lavage fluid was centrifuged at 170 × g for
10 min at 4◦C, the supernatant was removed, and the cell pellet
was re-suspended in 1 ml of PBS. One volume of a solution
containing 0.5% crystal violet dissolved in 30% acetic acid was
added to nine volumes of the cell suspension. The total number
of cells was determined by counting in a hematocytometer.
Following cytocentrifugation of the bronchoalveolar lavage
fluid, cells were stained with hematoxylin-eosin (Hema 3) for
determination of the differential cell numbers (Corrêa et al.,
2017).
Statistical Analyses
The results from in vivo evaluations are described as the
means ± SEM. Statistical evaluation of the data was carried
out using the one-way analysis of variance (ANOVA) followed
by Tukey’s post-test. A p-value that was lower than 0.05
was considered to be significant. All statistical analyses were
performed with the aid of GraphPad software (San Diego, CA,
United States).
RESULTS AND DISCUSSIONS
The design of LINS01 molecules was done considering the
presence of an aromatic nucleus (aryl or heteroaryl group)
linked to a polar moiety (imidazole, pyrrolidine, or piperazine)
observed in H3R and H4R ligands. The presence of an extra
lipophilic group attached to the polar moiety was also evaluated.
In a previous paper from Fernandes et al. (2011), a QSAR
study defined the importance of the R2 group for the affinity
for H4R in indolecarboxamides (e.g., chlorine in JNJ-7777120).
The role of the R2 group is also important for ligand affinity
to H3R, which are represented by the cyclopropyl ketone and
4-cyanophenyl groups in H3R ligands such as ciproxifan and
ABT-239, respectively (Cowart et al., 2004). Considering this,
the present set of molecules includes the substitutions not only
in piperazine nitrogen (R1), but also in the dihydrobenzofuran
moiety (R2) to determine preliminary SAR data for these
compounds. The results show that the R2 substituents can
play an important role in the binding affinities, being possibly
more important than the substituent R1 to drive the receptor
selectivity.
The 2-allylphenol was used as a starting material (Figure 2) for
compounds 1a–d, which was converted into the (2-iodomethyl)-
2,3-dihydrobenzofuran, as previously described by our group,
giving excellent yield (Table 1 and Supplementary Information)
(Corrêa et al., 2016, 2017). The iodinated dihydrobenzofuran
4a was then reacted with the corresponding piperazines in
considerable excess, giving moderate to good yields. The yields
of this step are presented in Table 1. A similar approach was
applied to prepare the commercially unavailable 1-allylpiperazine
5 (Supplementary Figure S1) with 40% yield. The 1-methyl and
1-phenyl piperazines are commercially available.
The compounds 1e–i were prepared starting from the
corresponding 4-substituted phenol, which was allylated using
allyl bromide, and then thermally isomerized through Claisen
rearrangement to give the corresponding 2-allylphenols, as
reported previously by Corrêa et al. (2017). Both steps resulted
in good to excellent yields (Table 1 and Supplementary
Information). With the 4-substituted 2-allylphenols, the final
compounds were prepared in the same fashion to compounds
1a–d (Corrêa et al., 2016).
The binding analyses were initially performed in the format
of a screening, to allow a quick assessment of the compounds
presenting relevant affinity for H3R and/or H4R (Supplementary
Figure S2). The results show that most of the compounds
presented higher affinity for H3R, and that only compounds
1e and 1f displayed considerable binding to H4R. Accordingly,
competition binding assays with full concentration–response
curves were performed with the selected compounds in the H3R
and H4R (Figure 3). The obtained K i values are in the range of
0.4–10 µM (Table 2).
Drug-likeness is a qualitative evaluation of a certain
compound for how drug-like it is with respect to some factors
such as bioavailability and potency based on the characteristics of
market drugs. The drug-likeness of the compounds was assessed
through the Lipinski’s rule-of-five (Lipinski et al., 2001) and
Veber’s rules (Veber et al., 2002) parameters as well as water
solubility. Lipinski’s rule-of-five proposes that a molecule should
have MW< 500, clogP< 5, HBD< 5 and HBA< 10 to have good
oral bioavailability. Veber’s rules include in these parameters
the TPSA < 140 and RotB < 10. The LINS01 compounds
fulfill all these parameters (Table 3), suggesting they should
have good bioavailability and possibly adequate pharmacokinetic
profile. The water solubility also determines the bioavailability
and other ADME processes. LINS01 molecules show adequate
water solubility, as indicated by the logS values (acceptable values
for > −4). With this regard, it is noteworthy the contribution
of methoxy group (1g) to enhanced water solubility. The
balanced hydrophilic–lipophilic character of LINS01 molecules
(as indicated by logP < 5 and logS > −4 values) suggests they
may have good pharmacokinetic behavior in vivo. Drug-likeness
scores corroborate to this estimation, since only positive values
were obtained (Table 3). Considering that market drugs and
non-drugs usually present, respectively, positive and negative
score values, LINS01 molecules can be considered promising
drug-like compounds to further optimization according to this
criteria.
In order to evaluate the potency of these compounds, metric
LE, LLE, LELP, and GE values were calculated (Table 4).
During drug discovery and development process, the MW and
lipophilicity usually increase in consonance with the potency.
This can be explained by the contribution of the inserted
non-hydrogen atoms to binding energy. LE is considered a
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FIGURE 3 | Binding and functional characterization of the compounds in the H3R and H4R. Competition dose–response binding curves for selected compounds
show that they presented lower affinity for either H3R (A) or H4R (B), as compared with histamine and selective ligands, with K i values varying from high nanomolar
to low micromolar. Functional assays in the H3R (C) reveal that all compounds do not trigger Gi activation, suggesting that they may behave as antagonists in this
receptor. In the H4R (D) a similar profile was observed. Antagonistic assays show that all tested compounds when preincubated at 10,000 nM were able to fully block
histamine activity in the H3R (E) and H4R (F), except for compound 1f that only partially blocked histamine activity on H4R, probably due to a weak agonistic effect
in high concentrations. Data were obtained from at least three independent experiments performed in duplicate. It is also interesting to note that either on H3R or on
H4R some compounds displayed a profile that suggests a mild inverse agonist activity, as can be observed by an inverse value of BRET as compared to histamine.
weighted value for non-hydrogen atoms contributions to binding
energy, which allows to compare affinities of molecules with
different sizes (Hopkins et al., 2014). Ligands with LE > 3 are
considered promising drug-like compounds. For comparison,
the mean value for oral drugs is around 4.5. Considering that
lipophilicity also influences on binding affinity, the LLE and LELP
values are lipophilicity-weighted LE values. The ideal LLE value
for an optimized drug candidate is ∼5–7, while LELP optimal
range values are between −10 and 10. GE is a measurement of
the binding efficiency for an added functional group in the parent
molecule (Verdonk and Rees, 2008). Accordingly, it represents
how much the added group contributed to overall affinity of the
molecule, considering the number of heavy atoms. For example,
a GE = 0.31 should represent at least a gain of 1.7-fold in
the potency of a small molecule (MW < 500). The higher
the GE value, the higher the contribution of the group to the
potency.
Regarding the H3R, the N-allyl derivative 1c showed the
highest affinity in the series, showing a pK i value of 6.40, followed
by the chloro, methoxy, and t-butyl derivatives 1e, 1g, and 1h,
with pK i values around 6.07, and the methyl derivative 1f with
pK i 6.15. The non-alkylated piperazine compound 1a, as well
as the N-phenyl derivatives 1d and 1i did not show appreciable
affinity for H3R, as mentioned before. The binding efficiencies
of the compounds 1b, 1c, and 1e–h are considered adequate,
since they present LE > 3 and with exception of compounds
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TABLE 2 | pK i values of tested compounds for H3R and H4R.
Compounds H3R pKia ± SEM H4R pKia ± SEM SIb H4R/H3R (Ki)
Histamine 8.53 ± 0.31 8.21 ± 0.29
Clobenpropit 9.25 ± 0.15 n.d.
JNJ-7777120 n.d. 8.25 ± 0.31
1a <5.0 <5.0 n.d.
1b 5.57 ± 0.17 <5.0 >3.7
1c 6.40 ± 0.21 <5.0 >25
1d <5.0 <5.0 n.d.
1e 6.07 ± 0.07 6.06 ± 0.06 1.1
1f 6.15 ± 0.08 5.00 ± 0.32 14
1g 6.06 ± 0.04 <5.0 >11
1h 6.07 ± 0.10 <5.0 > 11
1i <5.0 <5.0 n.d.
apKi values are presented as mean ± SEM of at least three independent
experiments. bSelectivity index. n.d.: Ki not determined.
1g and 1h, ≥4.5, indicating that although their low MW, their
efficiencies are comparable to a real drug. LELP and LLE values
suggest that lipophilicity is relatively high in these molecules, thus
suggesting that polar groups (which can improve binding affinity)
can be inserted for improvement in a future set of compounds.
We believe that H3R may have a considerable different binding
pocket than H4R in the R1 and R2 regions, which allow the
interaction of bulky hydrophobic groups (such as allyl in R1 and
t-butyl in R2). However, some steric hindrance effects might also
play a role (especially in the R1 region), limiting the interaction
of bulkier groups such as the phenyl group of 1d or 1i, but allows
the interaction of the allyl group present in 1c. The results also
suggest that the presence of an alkyl group linked to the polar
moiety of the molecule increases the affinity for H3R, as can be
seen by the high GE values for methyl (1b) and allyl (1c) groups
(Table 4).
Several 2-aminoethylbenzofurans have already been evaluated
as H3R ligands, showing good affinity (Cowart et al., 2004). These
compounds can be viewed as rigid analogs of ciproxifan, such
as ABT-239. Hence, the compounds here presented can also be
considered rigid derivatives of ciproxifan, but lacking aromaticity
in the furan ring. As observed in ABT-239 analogs, small alkyl
substituents in the polar moiety increase H3R affinity. This could
be the explanation for the poor affinity of 1a and moderate
affinities for 1c and the N-methyl derivatives 1e–h (Figure 3 and
Table 2).
Since ABT-239 and its analogs possess a 5-aryl substituted
benzofuran and better affinity, substituents at the 5-position
were explored to evaluate the role of the R2 group in the
dihydrobenzofuran derivatives. These data (Table 2) define the
importance of the R2 substituent in the binding affinity to H3R of
these compounds. Although there are no significant differences
between the affinity of compounds 1e–h to H3R, the affinity gain
caused by the R2 substitution can be noted by the pK i of the
non-substituted molecule 1b (5.57). Although compounds 1e–h
present quite similar pK i, the GE is very different among the
substituents (Table 4). Methyl group (1f) has shown the higher
contribution to binding efficacy in H3R, while t-butyl group (1h)
gave lower GE value. The presence of a polar group in R2 (such
TABLE 3 | Drug-likeness calculations for the compounds 1a–1i.
Compounds cLogP LogS TPSA HBA HBD RotB Drug-likeness scorea
1a 1.30 −1.23 24.50 3 1 2 0.86
1b 1.90 −1.20 15.71 3 0 2 1.21
1c 2.54 −2.26 15.71 3 0 4 0.90
1d 3.59 −2.63 15.71 3 0 3 1.19
1e 2.73 −2.05 15.71 3 0 2 1.49
1f 2.32 −1.48 15.71 3 0 2 1.10
1g 1.93 −1.31 24.94 4 0 3 1.33
1h 3.58 −2.94 15.71 3 0 3 1.09
1i 4.25 −3.48 15.71 3 0 3 1.35
aThe score was calculated using the MolSoft software algorithm.
TABLE 4 | Ligand metric analysis of the compounds tested for H3R and H4R.
Compounds H3R H4R
LE LELP LLE GE LE LELP LLE GE
1b 0.45 4.23 3.67 > 0.78a
1c 0.46 5.50 3.86 >0.63a
1e 0.46 5.90 3.34 0.69b 0.46 5.92 3.33 >1.45b
1f 0.47 4.96 3.83 0.80b 0.38 6.08 2.69 −
1g 0.44 4.42 4.13 0.34b
1h 0.40 9.04 2.49 0.17b
aGE of the group inserted on R1 of 1a. bGE of the group inserted on R2 of 1b.
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FIGURE 4 | Possible characteristics involved in H3R binding; green – aryl or heteroaryl; orange – polar group; blue – lipophilic group; yellow – bulky group. The
yellow group may define the selectivity for the H3R.
as methoxy in 1g) also suggests that hydrophobic groups are
preferred in this moiety, as indicated by GE= 0.34.
In summary, substitutions in R2 seem to play an important
role in H3R binding, since substituting the hydrogen in this
position led to improved affinity for the receptor. A rationale
SAR for the substitution pattern cannot be defined yet, and
further substituents must be explored. However, it is possible
to verify that possibly larger volume is tolerated in this region
of the molecule, such as the t-butyl group in 1h, which is
not tolerated when interacting to the H4R. Possibly, this group
presents the same role than the cyanophenyl group in ABT-239
(Figure 4), and maybe it could generate selectivity toward
H3R. Previous report from Dastmalchi et al. (2008) suggests
that bulkier molecules may display increased affinities for H3R,
possibly because there is a hydrophobic pocket nearby the R2
region which can be accessed by these groups, driving the
selectivity toward H3R over H4R. With exception of compound
1e, the molecules with substituents in R2 presented over 10-fold
selectivity for H3R as compared to H4R (Table 2). Other
molecules presenting other bulky groups in R2 are in progress
by our group to verify this possibility.
Regarding the affinity for H4R, compound 1e was the only
one to present affinity in the micromolar range (pK i 6.06).
Compound 1f has a K i in the range of ∼10,000 nM. The
remaining molecules presented negligible binding affinities, as
found in our initial screening approach (see Supplementary
Information) and aforementioned. Considering the similarity of
the presented compounds with the high affinity H4R antagonist
JNJ-7777120, it seems that the absence of the carbonyl group in
addition to the change of the indole ring to dihydrobenzofuran
is detrimental to the affinity of the ligands for H4R. In fact, the
changes in affinity caused by such changes corroborate previous
findings in benzofuran compounds (Engelhardt et al., 2012).
Previous reports (Venable et al., 2005; Engelhardt et al.,
2012) suggested that a methyl group is the best substituent in
the piperazine nitrogen of indolecarboxamide and benzimidazol
carboxamide series. Higher homologs or bulkier groups lead
to molecules with lower affinity for H4R. In the present series,
this pattern was also detected, since compounds 1e and 1f are
N-methyl derivatives. The LE values suggest these molecules
present good efficacy in the H4R binding affinity. Moreover, LELP
and LLE values also suggest that 1e and 1f represent drug-like
molecules that can still be optimized regarding the hydrophilic–
lipophilic balance. The present results suggest the R2 substituent
is more important to the binding affinity than the R1 group, and
bulkier groups (such as phenyl in 1d and 1h) lead to low binding
affinities (>10,000 nM) when binding H4R. Venable et al. (2005)
evaluated several H4R ligands with different substituents in R2
position, with chlorine being the group leading to an important
increase in the affinity. It is proposed that this atom performs a
key interaction with the binding pocket of H4R. In the present
report, this role was also observed, since compound 1e presented
the highest affinity in the series for this receptor. The insertion
of the chlorine atom resulted in more than 10-fold increase
in affinity and a very high GE value (Table 4). This suggests
that chlorine atom yielded in improved efficiency for 1e as H4R
ligand. In addition, when methyl is present in R2, the affinity
drops significantly, and bulkier groups led to total loss of affinity.
Accordingly, the H4R seems to present steric hindrance in the R2
region, which is not observed to H3R.
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FIGURE 5 | Effects of compounds 1d (LINS01005) and 1e (LINS01007) in the
(A) total inflammatory cell count and (B) eosinophil count obtained from
bronchoalveolar lavage (3 and 5 mg/kg); ##p < 0.01 relative to control group;
∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 relative to asthma group.
The functional activities of the LINS01 compounds were
performed to evaluate their possible actions as agonists of H3R
and/or H4R. Both H3R and H4R are GPCRs known to be Gi-
coupled. To determine the possible activity of the compounds as
agonists of this pathway, we used a BRET biosensor to assess and
quantify Gi1 isoform activation.
Regarding H3R, Figure 3C shows that all analyzed compounds
were unable to trigger Gi activation even in the highest tested
concentration (10,000 nM), likewise clobenpropit, a known H3R
antagonist. On the other hand, histamine (used as a positive
control) yielded a strong activation signal at 10 and 10,000 nM.
The results suggest that the compounds could act as antagonists
and block the activation triggered by histamine. This hypothesis
was indeed confirmed when cells expressing H3R were incubated
with the LINS01 compounds prior to stimulation with histamine.
As can be seen in Figure 3E, preincubation with any of the
tested compounds at the concentration of 10,000 nM fully
blocked histamine agonistic effect. The compounds were equally
efficacious in antagonizing histamine effects when compared to
clobenpropit, and therefore can be considered H3R antagonists.
Interestingly, some compounds displayed a profile of reversal
of BRET values, as compared to histamine alone, suggesting an
inverse agonist activity.
Analyses of functional activity on H4R showed that similarly to
JNJ-777120, a known H4R antagonist, the chlorinated compound
1e did not trigger Gi activation (Figure 3D). Possibly the specific
interaction of chlorine with H4R does not lead to activation
of the receptor, but when methyl group is present an agonist
mode interaction may occur and therefore a halogen-bonding
interaction is suggested rather than a hydrophobic interaction to
reach the antagonist binding mode. The role of chlorine in H4R
ligands was already widely studied, and it has been directly linked
to the antagonist activity on Gi as well as β-arrestin activation
(Nijmeijer et al., 2013). It is important to stress that histamine
itself was a poor stimulant of Gi in H4R (compare BRET values
from Figures 3C,D). When evaluating the potential to block
histamine activity, preincubation with the compound 1e at the
concentration of 10,000 nM fully blocked histamine agonistic
effect, similarly to the effect obtained for the H4R antagonist
JNJ-777120. The compound 1f, as described above, displays a
moderate agonistic effect, and therefore only partially reduced
histamine effect.
In order to evaluate the anti-inflammatory potential of the best
H4R blocker from the LINS01 set, compound 1e was tested in
a mouse asthma model and compared to the previously tested
compound 1d in two different doses (3 and 5 mg/kg, Figure 5).
Experimental murine asthma was induced by sensitization and
provocation with OVA. In a recent report (Corrêa et al., 2017),
we verified that 1d showed anti-inflammatory activity only at
5 mg/kg dose.
In the present work, we evaluated in parallel the compounds
1e (LINS01007) and 1d (LINS01005) to rodents. The reduction
in cell counts in both groups correlates well to the affinity to
H4R (see Figure 3B), supporting the involvement of this receptor
in the mechanism of the observed anti-inflammatory action.
The results presented in Figure 5 also suggest a dose-dependent
effect for compound 1d on both total cell and eosinophil counts
in bronchoalveolar lavage fluids, since a sounder reduction
in cellularity was observed in the highest concentration of
5 mg/kg. This reduction can be considered more relevant due
to the important reduction in eosinophilia. On the other hand,
compound 1e led to low counts in both doses. Possibly even in
the lower dose (3 mg/kg) the maximum efficacy was obtained.
In bronchoalveolar lavage fluids with experimental allergic
asthma, enhanced cell counts are commonly observed. In
particular, there is considerable increase in eosinophils, which are
commonly absent or in low density in the non-sensitized animals.
The involvement of H4R in experimental murine asthma model
has been demonstrated in several studies, including results with
JNJ-7777120, which was capable of reducing the inflammatory
infiltrations (especially eosinophils) and other asthma parameters
(Neumann et al., 2013). Considering that the pharmacological
profile obtained with LINS01 compounds in the total cell and
eosinophil counts is very similar to that obtained with the JNJ
compound, we believe the infiltration reductions are correlated to
H4R. Moreover, the higher activity observed to 1e also supports
this conclusion.
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CONCLUSION
In this study, we present nine LINS01 molecules with quite
simple structure, which have been evaluated concerning binding
affinities for the H3R and H4R, generating corresponding
receptor subtype selectivity values. We have also performed
functional analyses of Gi activation, which revealed that all tested
compounds act as antagonists to different extents on both H3R
and H4R. This is the first report regarding functional activity of
such compounds. SAR information concerning this chemotype
was generated and metric analyses suggest that future derivatives
with improved affinity can still be obtained. In vivo evaluation
in a mouse asthma model was performed and the potential anti-
inflammatory activity of such molecules is exemplified by 1e,
which showed to be highly effective at low doses.
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